Search Results
Ibrutinib for CLL with Deletion 17p
CLL: Optimal approaches for patients with deletion 17p
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Which CLL patients would benefit from intensive therapy?
Real-world analysis of the impact of del(17p) on ibrutinib efficacy in CLL
Karyotyping a CLL subset with ibrutinib susceptibility
Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up data
Ibrutinib Therapy in Chronic Lymphocytic Leukemia
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL
Update on venetoclax for CLL: How low can you go (MRD)?
